Democratising access to quantum computing: IQM Quantum Computers launches “IQM Spark” for universities and labs
30.8.2023 11:55:00 EEST | Business Wire | Press release
IQM Quantum Computers (IQM), the European leader in building quantum computers, today launched “IQM Spark,” comprising a superconducting quantum computer and tailored learning experiences for universities and research labs worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830120669/en/
IQM Spark quantum computer (Photo: Business Wire)
IQM Spark comes pre-installed with a 5-qubit quantum processing unit, with more options available allowing for a wide variety of research experiments.
To help universities kick-start their quantum program, in addition, universities will have free maintenance for one year, and IQM will also provide training for running the system and learning materials accessible through IQM Academy, a user-friendly online platform. With IQM Spark, students of all levels (bachelor, master, and PhD) will have the opportunity to learn hands-on about quantum computing.
Additionally, universities can also provide their students with the skillset needed for a quantum-enabled future by leveraging both hardware and software within the learning materials. With its technical track record and world-class expertise, IQM is also committed to collaborating with universities to drive advancements in quantum science.
Dr. Kuan Yen Tan, Chief Technology Officer and Co-founder of IQM Quantum Computers, said: “Since our inception, we’ve invested in and promoted quantum education and the advancement of research, and it’s apparent that universities around the globe need critical tools like IQM Spark to train the workforce needed for the next generation. Given the potential of quantum computing, the ecosystem will require a wide range of talent across electronics, chip fabrication, hardware design, and software engineering. We are confident that our system will facilitate the learning experience and engage students with the physical system.”
“We’ve designed this offering for universities and research labs to build up their quantum expertise and we believe that our system will not only perform fundamental quantum experiments and raise interest in Science, Technology, Engineering, and Mathematics (STEM) but we will also advance university science around quantum computing in general, while addressing the shortage of talent and providing value for the job market,” Dr. Björn Pötter, Head of Product at IQM Quantum Computers, points out.
IQM has already delivered 5-qubit quantum computers to some universities and research institutions, including the VTT Technical Research Centre of Finland and the Leibniz Supercomputing Centre in Germany. The quantum computer at VTT has been connected to LUMI, Europe’s most powerful supercomputer, hosted by the CSC - IT Center for Science.
“VTT and IQM successfully collaborated in delivering Finland’s first quantum computer in 2021. The 5-qubit quantum computer enables users to take the first steps in developing quantum algorithms and learn how to utilise the new technology in practice”, said Pekka Pursula, Research Manager in Quantum Technologies at VTT.
“On-premises quantum hardware is only available from a very limited number of vendors. This fact alone makes it hard for us to provide this leading-edge hardware to our scientists. Pricing and missing learning resources make it even harder to make this leading-edge technology available for educational purposes for our students,” said Prof. Dr. Dieter Kranzlmüller, Chairman of the Board of Directors of the Leibniz Supercomputing Centre, which caters to all universities of Bavaria in Germany.
“IQM Spark will address three major challenges: availability, learning resources, and affordability. In that way, universities can give practical experience to the next generation of quantum computing experts,” he added.
“Making on-premises quantum computer hardware available to our scientists and students as a low-barrier resource will give a boost to scientific progress and educate the next generation of quantum experts. This paves the way for students in Bavarian universities, such as Ludwig Maximilian University of Munich (LMU) and Technical University of Munich (TUM) students, to become entrepreneurs in the field of quantum technologies and live up to the excellence claim of the Munich universities,” he concluded.
About IQM Quantum Computers:
IQM is the European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific, co-design approach. IQM’s commercial quantum computers include Finland’s first commercial 54-qubit quantum computer with VTT, IQM-led consortium’s (Q-Exa) HPC quantum accelerator in Germany, and IQM processors will also be used in the first quantum accelerator in Spain. IQM has over 280 employees with offices in Paris, Madrid, Munich, Singapore, and Espoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830120669/en/
Contact information
Sylwia Barthel de Weydenthal, Head of Marketing and Communications
Email: press@meetiqm.com
Mobile: +358505966629
www.meetiqm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
